Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Whitehall Dimetapp Reformulations, New Products Drive U.S. Growth

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Whitehall-Robins' quick reformulation and shipment of PPA-free Dimetapp products spurred a 50.3% increase in the brand's domestic sales during the first quarter. Dimetapp sales reached $23.6 mil. in the U.S., compared to $15.7 mil. in the year-ago period, Whitehall parent American Home Products said April 25.

You may also be interested in...



GlaxoSmithKline Abreva $10 Mil. Sales Help Offset Smoking Cessation Woes

GlaxoSmithKline's Abreva posted $10 mil. in sales during the OTC cold sore medication's first full quarter on the U.S. market.

GlaxoSmithKline Abreva $10 Mil. Sales Help Offset Smoking Cessation Woes

GlaxoSmithKline's Abreva posted $10 mil. in sales during the OTC cold sore medication's first full quarter on the U.S. market.

GlaxoSmithKline Abreva $10 Mil. Sales Help Offset Smoking Cessation Woes

GlaxoSmithKline's Abreva posted $10 mil. in sales during the OTC cold sore medication's first full quarter on the U.S. market.

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS092500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By